厄贝沙坦氢氯噻嗪联合甲状腺素治疗老年重症心力衰竭

Irbesartan Hydrochlorothiazide Combined With Low-dose Thyroxine in the Treatment of Elderly Patients With Severe Heart Failure Clinical Value Analysis

目的探讨厄贝沙坦氢氯噻嗪联合小剂量甲状腺素治疗老年重症心力衰竭的临床价值。方法对我院特定时段内接诊的40例老年重症心力衰竭展开研究,按随机分组分为两组,给予常规治疗联合厄贝沙坦氢氯噻嗪治疗的为对照组,给予厄贝沙坦氢氯噻嗪联合小剂量甲状腺素治疗的为观察组,对比治疗疗效、治疗前后心功能指标变化情况。结果观察组总有效率为95.0%,对照组总有效率为70.0%,LVEDd、LVESd低于对照组,LVEF、SV、CO高于对照组,对比差异具有统计学意义,P <0.05。结论在老年重症心力衰竭患者的临床治疗过程中给予厄贝沙坦氢氯噻嗪联合小剂量甲状腺素治疗效果显著。

Objective To investigate the clinical value of irbesartan hydrochlorothiazide combined with low dose thyroxine in the treatment of elderly patients with severe heart failure.Methods Forty elderly patients with severe heart failure were randomly divided into two groups.Routine therapy plus irbesartan hydrochlorothiazide was given as control group.Irbesartan hydrochlorothiazide combined with low dose thyroxine was given as observation group.The curative effect and cardiac function before and after treatment were compared.Results The total effective rate of observation group was 95.0%,that of control group was 70.0%,LVEDd and LVESd were lower than control group,LVEF,SV and CO were higher than control group,the difference was statistically significant(P<0.05).Conclusion Irbesartan hydrochlorothiazide combined with low dose thyroxine is worth promoting in the treatment of elderly patients with severe heart failure.